There was no significant difference in the composite end point at @ days -LSB- @ % ( @/@ ) vs. @ % ( @/@ ) , P = @ -RSB- between the groups , however , there was a trend towards lower composite efficacy end points at @ months in tirofiban group compared to control group -LSB- @ % ( @/@ ) vs. @ % ( @/@ ) , P = @ -RSB- .